Myeloid cells constitute essential components within the immunosuppressive microenvironment of various tumors, significantly influencing cancer progression and resistance to therapeutic interventions. Among these cells, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs) prominently modulate anti-tumor immunity and contribute to unfavorable clinical outcomes. Recent studies have identified extensive involvement of these myeloid subsets in rendering resistance to therapies such as chemotherapy, immune checkpoint blockade, and chimeric antigen receptor T-cell (CAR-T) therapy. Despite significant efforts in clinical trials employing various myeloid cell modulatory agents, overall successes have been limited. Nevertheless, recent preclinical and early clinical evidence highlights promising results from novel strategies targeting immunometabolic pathways, epigenetic mechanisms, chemokine signaling, and immunosuppressive factors intrinsic to tumor-associated myeloid cells. Complementary approaches, including myeloid cell differentiation enhancement or targeted depletion strategies, also present potential avenues for therapeutic improvement, necessitating deeper investigations into their clinical translational capacity.
This Research Topic aims to deepen our understanding of context-dependent roles and mechanistic pathways underlying myeloid cell-mediated immunosuppression and therapeutic resistance. A major objective is to identify optimal strategies to modulate myeloid cell populations across different tumor types and patient subgroups to effectively enhance therapeutic outcomes. The collection seeks studies uncovering cellular and molecular mediators of therapeutic failure driven by myeloid cells, alongside exploration of combinational regimens integrating myeloid-targeted treatments with lymphocyte-based immunotherapies.
To gather further insights within the spectrum of myeloid cell biology and tumor immunosuppression, we welcome research encompassing both basic and clinical investigations. Manuscripts are invited to address themes, including but not limited to:
• Novel therapeutic agents targeting tumor-modified myeloid cells, particularly MDSCs, TAMs, and TANs;
• Combinatory treatment strategies integrating myeloid cell modulation with lymphocyte-centric immunotherapies (immune checkpoint inhibitors, CAR-T, CAR-NK therapies);
• Mechanistic insights into myeloid cell-driven resistance to cancer therapies;
• Development and application of innovative technologies for targeting and regulating myeloid cell functions;
• Tumor profiling and patient stratification strategies based on specific myeloid cell signatures across cancer types.
We encourage submission of Original Research articles, Reviews, and other relevant article types exploring these critical facets of tumor-associated myeloid cell biology and immunotherapeutic intervention.
Myeloid cells constitute essential components within the immunosuppressive microenvironment of various tumors, significantly influencing cancer progression and resistance to therapeutic interventions. Among these cells, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs) prominently modulate anti-tumor immunity and contribute to unfavorable clinical outcomes. Recent studies have identified extensive involvement of these myeloid subsets in rendering resistance to therapies such as chemotherapy, immune checkpoint blockade, and chimeric antigen receptor T-cell (CAR-T) therapy. Despite significant efforts in clinical trials employing various myeloid cell modulatory agents, overall successes have been limited. Nevertheless, recent preclinical and early clinical evidence highlights promising results from novel strategies targeting immunometabolic pathways, epigenetic mechanisms, chemokine signaling, and immunosuppressive factors intrinsic to tumor-associated myeloid cells. Complementary approaches, including myeloid cell differentiation enhancement or targeted depletion strategies, also present potential avenues for therapeutic improvement, necessitating deeper investigations into their clinical translational capacity.
This Research Topic aims to deepen our understanding of context-dependent roles and mechanistic pathways underlying myeloid cell-mediated immunosuppression and therapeutic resistance. A major objective is to identify optimal strategies to modulate myeloid cell populations across different tumor types and patient subgroups to effectively enhance therapeutic outcomes. The collection seeks studies uncovering cellular and molecular mediators of therapeutic failure driven by myeloid cells, alongside exploration of combinational regimens integrating myeloid-targeted treatments with lymphocyte-based immunotherapies.
To gather further insights within the spectrum of myeloid cell biology and tumor immunosuppression, we welcome research encompassing both basic and clinical investigations. Manuscripts are invited to address themes, including but not limited to:
• Novel therapeutic agents targeting tumor-modified myeloid cells, particularly MDSCs, TAMs, and TANs;
• Combinatory treatment strategies integrating myeloid cell modulation with lymphocyte-centric immunotherapies (immune checkpoint inhibitors, CAR-T, CAR-NK therapies);
• Mechanistic insights into myeloid cell-driven resistance to cancer therapies;
• Development and application of innovative technologies for targeting and regulating myeloid cell functions;
• Tumor profiling and patient stratification strategies based on specific myeloid cell signatures across cancer types.
We encourage submission of Original Research articles, Reviews, and other relevant article types exploring these critical facets of tumor-associated myeloid cell biology and immunotherapeutic intervention.